tbuckley/cabot-search huggingface dataset:
A nomogram for individualized estimation of survival among adult patients with adrenocortical carcinoma after surgery: a retrospective analysis and multicenter validation study
Authors: Jianqiu Kong, Junjiong Zheng, Jinhua Cai, Shaoxu Wu, Xiayao Diao, Weibin Xie, Xiong Chen, Chenyi Liao, Hao Yu, Xinxiang Fan, Chaowen Huang, Zhuowei Liu, Wei Chen, Qiang Lv, Haide Qin, Jian Huang, Tianxin Lin
Journal: Cancer Communications (2019)

Clinical outcome of adrenocortical carcinoma (ACC) varies because of its heterogeneous nature and reliable prognostic prediction model for adult ACC patients is limited. The objective of this study was to develop and externally validate a nomogram for overall survival (OS) prediction in adult patients with ACC after surgery. Based on the data from the Surveillance Epidemiology, and End Results (SEER) database, adults patients diagnosed with ACC between January 1988 and December 2015 were identified and classified into a training set, comprised of 404 patients diagnosed between January 2007 and December 2015, and an internal validation set, comprised of 318 patients diagnosed between January 1988 and December 2006. The endpoint of this study was OS. The nomogram was developed using a multivariate Cox proportional hazards regression algorithm in the training set and its performance was evaluated in terms of its discriminative ability, calibration, and clinical usefulness. The nomogram was then validated using the internal SEER validation, also externally validated using the Cancer Genome Atlas set (TCGA, 82 patients diagnosed between 1998 and 2012) and a Chinese multicenter cohort dataset (82 patients diagnosed between December 2002 and May 2018), respectively. Age at diagnosis, T stage, N stage, and M stage were identified as independent predictors for OS. A nomogram incorporating these four predictors was constructed using the training set and demonstrated good calibration and discrimination (C-index 95% confidence interval [CI], 0.715 [0.679–0.751]), which was validated in the internal validation set (C-index [95% CI], 0.672 [0.637–0.707]), the TCGA set (C-index [95% CI], 0.810 [0.732–0.888]) and the Chinese multicenter set (C-index [95% CI], 0.726 [0.633–0.819]), respectively. Encouragingly, the nomogram was able to successfully distinguished patients with a high-risk of mortality in all enrolled patients and in the subgroup analyses. Decision curve analysis indicated that the nomogram was clinically useful and applicable. The study presents a nomogram that incorporates clinicopathological predictors, which can accurately predict the OS of adult ACC patients after surgery. This model and the corresponding risk classification system have the potential to guide therapy decisions after surgery.
Study Clarifies Cancer Risk Among People With Psoriasis
Authors: Rebecca Voelker
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Multidrug Transporter MRP4/ABCC4 Involved in the Leukemia Clinical Course Specifies the Novel PEL Human Blood Group System
Authors: Slim Azouzi, Mahmoud Mikdar, Patricia Hermand-Tournamille, Emilie-Fleur Gautier, Virginie Salnot, Alexandra Willemetz, Gaël Nicolas, Cedric Vrignaud, Alexandre Raneri, Patrick Mayeux, Christine Bole-Feysot, Patrick Nitschke, Jean-Pierre Cartron, Yves Colin Aronovicz, Olivier Hermine, Gabriele Jedlitschky, Marc Cloutier, Jessica Constanzo-Yanez, Carole Ethier, Nancy Robitaille, Maryse St-Louis, Caroline Le Van Kim, Thierry Peyrard
Journal: Blood (2019)
Lipid Lowering by Diet Reduces Matrix Metalloproteinase Activity and Increases Collagen Content of Rabbit Atheroma
Authors: Masanori Aikawa, Elena Rabkin, Yoshikatsu Okada, Sami J. Voglic, Steven K. Clinton, Constance E. Brinckerhoff, Galina K. Sukhova, Peter Libby
Journal: Circulation (1998)

Background —Proteolytic enzyme activity in lipid-rich atheroma may promote plaque rupture and precipitate acute coronary syndromes. This study tested the hypothesis that lipid lowering stabilizes plaques by reducing proteolytic activity. Methods and Results —We produced experimental atheroma in 33 rabbits by balloon injury and an atherogenic diet (0.3% cholesterol and 4.7% coconut oil) for 4 months. At that time, 15 rabbits were killed (baseline group). The remaining animals were divided into two groups: a hyperlipemic group continued to consume a cholesterol-enriched diet (0.05% to 0.2%) for 16 more months (n=5) and a lipid-lowering group consumed a purified chow diet with no added cholesterol or fat for 8 (n=3) or 16 months (n=10). Macrophage accumulation and interstitial collagenase (matrix metalloproteinase-1, MMP-1) expression in the lesion were measured by quantitative image analysis of standardized sections of immunostained aortas. Baseline lesions expressed high levels of MMP-1 and contained many macrophages. These features of plaque instability persisted in the hyperlipemic group. However, the lipid-lowering group showed progressive reduction in both macrophage content and MMP-1 immunoreactivity with time. Aortic rings of the baseline and hyperlipemic groups elaborated gelatinolytic, caseinolytic, and elastinolytic activity attributable to MMP-2, MMP-3, or MMP-9, monitored by SDS-PAGE zymography. Proteolytic activity decreased markedly in the lipid-lowering group. Aortic content of interstitial collagen, determined by sirius red staining, increased in the lipid-lowering group compared with the baseline or continued hyperlipemic groups, indicating that lipid lowering reinforced the fibrous skeleton of the atheroma. Conclusions —These results establish a mechanism by which lipid lowering may stabilize vulnerable plaques by reduced expression and activity of enzymes that degrade the arterial extracellular matrix and render atheroma less susceptible to disruption and thrombosis by favoring collagen accumulation in the fibrous cap.
De-escalating axillary surgery according to neoadjuvant single or dual HER2 blockade in clinically node-positive, HER2-positive breast cancer
Authors: C. Cha, D. Kim, J. Lee, S. Park, S.J. Bae, J.Y. Kim, S.G. Ahn, H.S. Park, S. Park, S.I. Kim, Y.U. Cho, J. Jeong
Journal: Annals of Oncology (2019)
Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup analysis of ICARIA-MM study
Authors: T. Ikeda, K. Sunami, S.-Y. Huang, M.-C. Wang, Y.I. Koh, C.G. Min, S.-P. Yeh, M. Matsumoto, M. Uchiyama, S. Iyama, C. Shimazaki, J.H. Lee, K.H. Kim, H. Kaneko, J.S. Kim, T.-L. Lin, F. Campana, K. Tada, S. Iida, K. Suzuki
Journal: Annals of Oncology (2019)
Cardiovascular and non‐cardiovascular death distinction: the utility of troponin beyond N‐terminal pro‐B‐type natriuretic peptide. Findings from the BIOSTAT‐CHF study
Authors: João Pedro Ferreira, Wouter Ouwerkerk, Jasper Tromp, Leong Ng, Kenneth Dickstein, Stefan Anker, Gerasimos Filippatos, John G. Cleland, Marco Metra, Dirk J. van Veldhuisen, Adriaan A. Voors, Faiez Zannad
Journal: European Journal of Heart Failure (2019)
Should This Patient Be Screened for Atrial Fibrillation?
Authors: Risa B. Burns, Peter Zimetbaum, Steven A. Lubitz, Gerald W. Smetana
Journal: Annals of Internal Medicine (2019)

This article has been corrected. The original version (PDF) is appended to this article as a Supplement. Atrial fibrillation (AFib) is the most common type of cardiac arrhythmia, affecting 2.7 million to 6.1 million persons in the United States. Although some persons with AFib have no symptoms, others do. For those without symptoms, AFib may be detected by 12-lead electrocardiogram (ECG), single-lead monitors (such as ambulatory blood pressure monitors and pulse oximeters), or consumer devices (such as wearable monitors and smartphones). Pulse palpation and heart auscultation also may detect AFib. In a systematic review, screening with ECG identified more new cases of AFib than no screening. Atrial fibrillation is an important cause of stroke, and without anticoagulant treatment, patients with AFib have approximately a 5-fold increased risk for stroke. The U.S. Preventive Services Task Force reviewed the benefits and harms of ECG screening for AFib in adults aged 65 years or older and found inadequate evidence that ECG identifies AFib more effectively than usual care. This conclusion is in contrast to guidelines from the European Society of Cardiology and the National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand, which found that active screening for AFib in patients older than 65 years may be useful. Here, 2 cardiologists discuss the risks and benefits of screening for AFib, if and when they would recommend screening, and whether they would recommend anticoagulation for a patient with screen-detected AFib.
MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells
Authors: Edith Schneider, Nicole Pochert, Christoph Ruess, Liam MacPhee, Leo Escano, Christina Miller, Kathrin Krowiorz, Erik Delsing Malmberg, Alireza Heravi-Moussavi, Alireza Lorzadeh, Arghavan Ashouri, Sarah Grasedieck, Nadine Sperb, Pradeep Kumar Kopparapu, Sebastian Iben, Anna Staffas, Ping Xiang, Reinhild Rösler, Meena Kanduri, Erik Larsson, Linda Fogelstrand, Hartmut Döhner, Konstanze Döhner, Sebastian Wiese, Martin Hirst, R. Keith Humphries, Lars Palmqvist, Florian Kuchenbauer, Arefeh Rouhi
Journal: Leukemia (2019)
Post-translational modification of Parkin and its research progress in cancer
Authors: Dan Ding, Xiang Ao, Ying Liu, Yuan-Yong Wang, Hong-Ge Fa, Meng-Yu Wang, Yu-Qi He, Jian-Xun Wang
Journal: Cancer Communications (2019)

Clinical practice has shown that Parkin is the major causative gene found in an autosomal recessive juvenile parkinsonism (AR-JP) via Parkin mutations and that the Parkin protein is the core expression product of the Parkin gene, which itself belongs to an E3 ubiquitin ligase. Since the discovery of the Parkin gene in the late 1990s, researchers in many countries have begun extensive research on this gene and found that in addition to AR-JP, the Parkin gene is associated with many diseases, including type 2 diabetes, leprosy, Alzheimer's, autism, and cancer. Recent studies have found that the loss or dysfunction of Parkin has a certain relationship with tumorigenesis. In general, the Parkin gene, a well-established tumor suppressor, is deficient and mutated in a variety of malignancies. Parkin overexpression inhibits tumor cell growth and promotes apoptosis. However, the functions of Parkin in tumorigenesis and its regulatory mechanisms are still not fully understood. This article describes the structure, functions, and post-translational modifications of Parkin, and summarizes the recent advances in the tumor suppressive function of Parkin and its underlying mechanisms.
Association of Anticholinergic Drug Exposure With Increased Occurrence of Dementia—Reply
Authors: Carol A. C. Coupland, Michael Moore, Julia Hippisley-Cox
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Maternal and Infant Outcomes After Different Methods of Umbilical Cord Management
Authors: Heike Rabe, Ola Andersson
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase I study to evaluate safety and efficacy of BPI-7711 in EGFRm+/T790M+ advanced or recurrent NSCLC patients
Authors: Y. Shi, J. Fang, Y. Shu, D. Wang, H. Yu, Y. Zhao, L. Zhang, B. Zhu, X. Li, G. Chen, J. Shi, R. Zheng, J. Huang, S. Yang, J. Long, W. Gao, M. Greco, G. Hu, X. Li
Journal: Annals of Oncology (2019)
Labour promises increased NHS funding and free dental care
Authors: Abi Rimmer
Journal: BMJ (2019)

We’re another week into the election campaign, and politicians from the two major parties are still battling it out to prove who loves the NHS more.

The shadow health secretary, Jonathan Ashworth, and shadow chancellor, John McDonnell, have announced that the Labour Party would increase NHS spending by £26bn (€30.4bn; $33.4bn) in real terms between now and 2023-24 if elected next month, outspending the Conservatives’ existing commitment by more than £6bn.1

Labour’s settlement would increase the budget for England’s Department of Health and Social Care by an …
Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain
Authors: A. González-Díaz, J. Càmara, M. Ercibengoa, E. Cercenado, N. Larrosa, M.D. Quesada, D. Fontanals, M. Cubero, J.M. Marimón, J. Yuste, C. Ardanuy
Journal: Clinical Microbiology and Infection (2019)
NCF1-339 polymorphism and systemic lupus erythematosus
Authors: Beuy Joob, Viroj Wiwanitkit
Journal: Annals of the Rheumatic Diseases (2019)

NCF1-339 polymorphism and systemic lupus erythematosusWe read the publication on 'NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome (APS) in systemic lupus erythematosus (SLE)' with great interest. 1Linge et al concluded that "we revealed a striking connection between the ROS deficient NCF1-339 genotypes and the presence of phospholipid antibodies and APS". 1 The NCF1-339 rs201802880 polymorphism is a single mutation that might cause the molecular change.Due to the mutation, the molecular weight change and the alteration of the phenotypic expression is the result.In the present report, Linge et al studied on only one genetic polymorphism and did not assess the possible effects of other genetic polymorphisms that might have clinical association with SLE.The examples of those genetic polymorphisms are paraoxonase-1 gene and PAL-1 polymorphisms. 2 3 Further studies to access the possible confounding factors of other genetic polymorphisms are required.
A population pharmacokinetic model: Assessment of pharmacokinetic similarity of HLX01 and rituximab in diffuse large B-cell lymphoma
Authors: Y. Shi, Y. Qin, S. Zhao, P. Hu, X. Zeng, X. Zhang, W. Jiang, S. Liu, E. Liu, K. Chai, A. Luk, D. Yao
Journal: Annals of Oncology (2019)
Life Expectancy and Mortality Rates in the United States, 1959-2017
Authors: Steven H. Woolf, Heidi Schoomaker
Journal: JAMA (2019)

US life expectancy has not kept pace with that of other wealthy countries and is now decreasing.To examine vital statistics and review the history of changes in US life expectancy and increasing mortality rates; and to identify potential contributing factors, drawing insights from current literature and an analysis of state-level trends.Life expectancy data for 1959-2016 and cause-specific mortality rates for 1999-2017 were obtained from the US Mortality Database and CDC WONDER, respectively. The analysis focused on midlife deaths (ages 25-64 years), stratified by sex, race/ethnicity, socioeconomic status, and geography (including the 50 states). Published research from January 1990 through August 2019 that examined relevant mortality trends and potential contributory factors was examined.Between 1959 and 2016, US life expectancy increased from 69.9 years to 78.9 years but declined for 3 consecutive years after 2014. The recent decrease in US life expectancy culminated a period of increasing cause-specific mortality among adults aged 25 to 64 years that began in the 1990s, ultimately producing an increase in all-cause mortality that began in 2010. During 2010-2017, midlife all-cause mortality rates increased from 328.5 deaths/100 000 to 348.2 deaths/100 000. By 2014, midlife mortality was increasing across all racial groups, caused by drug overdoses, alcohol abuse, suicides, and a diverse list of organ system diseases. The largest relative increases in midlife mortality rates occurred in New England (New Hampshire, 23.3%; Maine, 20.7%; Vermont, 19.9%) and the Ohio Valley (West Virginia, 23.0%; Ohio, 21.6%; Indiana, 14.8%; Kentucky, 14.7%). The increase in midlife mortality during 2010-2017 was associated with an estimated 33 307 excess US deaths, 32.8% of which occurred in 4 Ohio Valley states.US life expectancy increased for most of the past 60 years, but the rate of increase slowed over time and life expectancy decreased after 2014. A major contributor has been an increase in mortality from specific causes (eg, drug overdoses, suicides, organ system diseases) among young and middle-aged adults of all racial groups, with an onset as early as the 1990s and with the largest relative increases occurring in the Ohio Valley and New England. The implications for public health and the economy are substantial, making it vital to understand the underlying causes.
A piece of my mind. Jerico Springs, Missouri
Authors: B. Swager
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Authors: Amer M. Zeidan, Gary J. Schiller, Tara L. Lin, Pamela S. Becker, Prapti A. Patel, Eunice S. Wang, Alexander I. Spira, Michaela L. Tsai, Maya Ridinger, Peter J Croucher, Mark Erlander, Sandra L Silberman
Journal: Blood (2019)
Increased Microglial Exosomal miR-124-3p Alleviates Neurodegeneration and Improves Cognitive Outcome after rmTBI
Authors: Xintong Ge, Mengtian Guo, Tianpeng Hu, Wenzhu Li, Shan Huang, Zhenyu Yin, Ying Li, Fanglian Chen, Luoyun Zhu, Chunsheng Kang, Rongcai Jiang, Ping Lei, Jianning Zhang
Journal: Molecular Therapy (2019)

Repetitive mild traumatic brain injury (rmTBI) is considered to be an important risk factor for long-term neurodegenerative disorders such as Alzheimer's disease, which is characterized by β-amyloid abnormalities and impaired cognitive function. Microglial exosomes have been reported to be involved in the transportation, distribution, and clearance of β-amyloid in Alzheimer's disease. However, their impacts on the development of neurodegeneration after rmTBI are not yet known. The role of miRNAs in microglial exosomes on regulating post-traumatic neurodegeneration was investigated in the present study. We demonstrated that miR-124-3p level in microglial exosomes from injured brain was significantly altered in the acute, sub-acute, and chronic phases after rmTBI. In in vitro experiments, microglial exosomes with upregulated miR-124-3p (EXO-124) alleviated neurodegeneration in repetitive scratch-injured neurons. The effects were exerted by miR-124-3p targeting Rela, an inhibitory transcription factor of ApoE that promotes the β-amyloid proteolytic breakdown, thereby inhibiting β-amyloid abnormalities. In mice with rmTBI, the intravenously injected microglial exosomes were taken up by neurons in injured brain. Besides, miR-124-3p in the exosomes was transferred into hippocampal neurons and alleviated neurodegeneration by targeting the Rela/ApoE signaling pathway. Consequently, EXO-124 treatments improved the cognitive outcome after rmTBI, suggesting a promising therapeutic strategy for future clinical translation.